Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team

Rahul Aggarwal, Tomasz (Tom) Beer, Martin Gleave, Joshua M. Stuart, Matthew Rettig, Christopher P. Evans, Jack Youngren, Joshi Alumkal, Jiaoti Huang, George Thomas, Owen Witte, Eric J. Small

Research output: Contribution to journalArticle

5 Scopus citations


The Stand Up 2 Cancer/Prostate Cancer Foundation–funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.

Original languageEnglish (US)
Pages (from-to)469-471
Number of pages3
JournalEuropean Urology Focus
Issue number5
Publication statusPublished - Dec 1 2016



  • (AR) pathway inhibitors
  • abiraterone
  • enzalutamide

ASJC Scopus subject areas

  • Urology

Cite this